|
1
|
Bae JM, Kim JH, Kwak Y, Lee DW, Cha Y, Wen
X, Lee TH, Cho NY, Jeong SY, Park KJ, et al: Distinct clinical
outcomes of two CIMP-positive colorectal cancer subtypes based on a
revised CIMP classification system. Br J Cancer. 116:1012–1020.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hadjipetrou A, Anyfantakis D, Galanakis
CG, Kastanakis M and Kastanakis S: Colorectal cancer, screening and
primary care: A mini literature review. World J Gastroenterol.
23:6049–6058. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Haraldsdottir S, Einarsdottir HM,
Smaradottir A, Gunnlaugsson A and Halfdanarson TR: Colorectal
cancer - review. Laeknabladid. 100:75–82. 2014.(In Icelandic).
PubMed/NCBI
|
|
4
|
Lieberman D, Ladabaum U, Cruz-Correa M,
Ginsburg C, Inadomi JM, Kim LS, Giardiello FM and Wender RC:
Screening for colorectal cancer and evolving issues for physicians
and patients: A Review. JAMA. 316:2135–2145. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu W, Sun Y, Zhang L and Xing BC:
Negative surgical margin improved long-term survival of colorectal
cancer liver metastases after hepatic resection: A systematic
review and meta-analysis. Int J Colorectal Dis. 30:1365–1373. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Massat NJ, Moss SM, Halloran SP and Duffy
SW: Screening and primary prevention of colorectal cancer: A review
of sex-specific and site-specific differences. J Med Screen.
20:125–148. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bonfrate L, Altomare DF, Di Lena M,
Travaglio E, Rotelli MT, De Luca A and Portincasa P: MicroRNA in
colorectal cancer: New perspectives for diagnosis, prognosis and
treatment. J Gastrointestin Liver Dis. 22:311–320. 2013.PubMed/NCBI
|
|
8
|
Karatas OF, Suer I, Yuceturk B, Yilmaz M,
Hajiyev Y, Creighton CJ, Ittmann M and Ozen M: The role of miR-145
in stem cell characteristics of human laryngeal squamous cell
carcinoma Hep-2 cells. Tumour Biol. 37:4183–4192. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu L, Li Q, Xu D, Wang Q, An Y, Du Q,
Zhang J, Zhu Y and Miao Y: hsa-miR-141 downregulates TM4SF1 to
inhibit pancreatic cancer cell invasion and migration. Int J Oncol.
44:459–466. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang G, Shen N, Cheng L, Lin J and Li K:
Downregulation of miR-22 acts as an unfavorable prognostic
biomarker in osteosarcoma. Tumour Biol. 36:7891–7895. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bai QL, Hu CW, Wang XR, Shang JX and Yin
GF: miR-616 promotes proliferation and inhibits apoptosis in glioma
cells by suppressing expression of SOX7 via the Wnt signaling
pathway. Eur Rev Med Pharmacol Sci. 21:5630–5637. 2017.PubMed/NCBI
|
|
12
|
Wang Z, Liao H, Deng Z, Yang P, Du N,
Zhanng Y and Ren H: miRNA-205 affects infiltration and metastasis
of breast cancer. Biochem Biophys Res Commun. 441:139–143. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Staton CA, Kumar I, Reed MW and Brown NJ:
Neuropilins in physiological and pathological angiogenesis. J
Pathol. 212:237–248. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pellet-Many C, Frankel P, Jia H and
Zachary I: Neuropilins: Structure, function and role in disease.
Biochem J. 411:211–226. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Drabkin HA, Starkova J and Gemmill RM: A
triad of NRP2, DLX and p53 proteins in lung cancer metastasis.
Oncotarget. 8:96464–96465. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fujii T, Shimada K, Asano A, Tatsumi Y,
Yamaguchi N, Yamazaki M and Konishi N: MicroRNA-331-3p suppresses
cervical cancer cell proliferation and E6/E7 expression by
targeting NRP2. Int J Mol Sci. 17:172016. View Article : Google Scholar
|
|
17
|
Yasuoka H, Kodama R, Tsujimoto M,
Yoshidome K, Akamatsu H, Nakahara M, Inagaki M, Sanke T and
Nakamura Y: Neuropilin-2 expression in breast cancer: Correlation
with lymph node metastasis, poor prognosis, and regulation of CXCR4
expression. BMC Cancer. 9:2202009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2 (-Delta DeltaC(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dweep H, Sticht C, Pandey P and Gretz N:
miRWalk - database: Prediction of possible miRNA binding sites by
‘walking’ the genes of three genomes. J Biomed Inform. 44:839–847.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Burstein HJ and Schwartz RS: Molecular
origins of cancer. N Engl J Med. 358:5272008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
El Sharawy A, Röder C, Becker T, Habermann
JK, Schreiber S, Rosenstiel P and Kalthoff H: Concentration of
circulating miRNA-containing particles in serum enhances miRNA
detection and reflects CRC tissue-related deregulations.
Oncotarget. 7:75353–75365. 2016.PubMed/NCBI
|
|
22
|
Suzuki HI, Katsura A, Matsuyama H and
Miyazono K: MicroRNA regulons in tumor microenvironment. Oncogene.
34:3085–3094. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Epis MR, Giles KM, Beveridge DJ,
Richardson KL, Candy PA, Stuart LM, Bentel J, Cohen RJ and Leedman
PJ: miR-331-3p and Aurora kinase inhibitor II co-treatment
suppresses prostate cancer tumorigenesis and progression.
Oncotarget. 8:55116–55134. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen L, Chu F, Cao Y, Shao J and Wang F:
Serum miR-182 and miR-331-3p as diagnostic and prognostic markers
in patients with hepatocellular carcinoma. Tumour Biol.
36:7439–7447. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cao Y, Zhang J, Xiong D, Wang D, Wu T,
Huang A and Tang H: Hsa-miR-331-3p inhibits VHL expression by
directly targeting its mRNA 3-UTR in HCC cell lines. Acta Biochim
Pol. 62:77–82. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zachary IC, Frankel P, Evans IM and
Pellet-Many C: The role of neuropilins in cell signalling. Biochem
Soc Trans. 37:1171–1178. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rossignol M, Gagnon ML and Klagsbrun M:
Genomic organization of human neuropilin-1 and neuropilin-2 genes:
Identification and distribution of splice variants and soluble
isoforms. Genomics. 70:211–222. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Niland S and Eble JA: Neuropilins in the
context of tumor vasculature. Int J Mol Sci. 20:202019. View Article : Google Scholar
|
|
29
|
Favier B, Alam A, Barron P, Bonnin J,
Laboudie P, Fons P, Mandron M, Herault JP, Neufeld G, Savi P, et
al: Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes
human endothelial cell survival and migration. Blood.
108:1243–1250. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Caunt M, Mak J, Liang WC, Stawicki S, Pan
Q, Tong RK, Kowalski J, Ho C, Reslan HB, Ross J, et al: Blocking
neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell.
13:331–342. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fung TM, Ng KY, Tong M, Chen JN, Chai S,
Chan KT, Law S, Lee NP, Choi MY, Li B, et al: Neuropilin-2 promotes
tumourigenicity and metastasis in oesophageal squamous cell
carcinoma through ERK-MAPK-ETV4-MMP-E-cadherin deregulation. J
Pathol. 239:309–319. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dallas NA, Gray MJ, Xia L, Fan F, van
Buren G II, Gaur P, Samuel S, Lim SJ, Arumugam T, Ramachandran V,
et al: Neuropilin-2-mediated tumor growth and angiogenesis in
pancreatic adenocarcinoma. Clin Cancer Res. 14:8052–8060. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Moriarty WF, Kim E, Gerber SA, Hammers H
and Alani RM: Neuropilin-2 promotes melanoma growth and progression
in vivo. Melanoma Res. 26:321–328. 2016. View Article : Google Scholar : PubMed/NCBI
|
